Alkermes Inc. plc
ALKS Real Time Price USD$ALKS is featured in our Congress Long-Short and U.S. House Long-Short strategies.
All StrategiesRecent trades of ALKS by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Gilbert Ray Cisneros, Jr. House / D | Purchase $15,001 - $50,000 | Jul 30, 2026 |
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in ALKS holdings by institutional investors
Quarterly net insider trading by ALKS's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Former government officials who have lobbied for ALKS
73 former government officials from 40 congressional offices at 19 lobbying firms have lobbied for ALKS, most recently Aug 13, 2026.
-
Joel White House New Staff Director, Ways & Means Health Subcommittee; L.A. for Rep. Jim Greenwood; L.A. for Rep. Chris Shays -
Sarah Egge Senate Sarah: 1998-2000 Legislative Assistant to Senator Bob Kerrey; 2001-2012 Senior Budget Analyst for Democratic Staff of the Senate Budget Committee (Kent Conrad); Fall 2011, Deputy Staff Director, Joint Select Committee for Deficit Reduction -
Daniel Todd Senate Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid
-
Nicholas Uehlecke House Senior Advisor, Dept. of Health and Human Services; Professional Staff/Sr. Legislative Assistant, House Ways and Means Subcommittee
-
Eric Bergren House Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker -
Katherine Cotton House Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie
-
Paul Edattel House Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg -
Remy Mason Senate Senior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren; Intern to Rep. Allyson Schwartz
ALKS Estimated quarterly lobbying spending
ALKS Revenue by Segment or Geography
New ALKS patent grants
-
Patent Title: Substituted carbamate macrocyclic compounds and related methods of treatment May. 26, 2026
-
Patent Title: Substituted piperidino compounds and related methods of treatment Oct. 14, 2025
-
Patent Title: Substituted macrocyclic compounds and related methods of treatment Aug. 06, 2024
-
Patent Title: Substituted macrocyclic compounds and related methods of treatment Jun. 11, 2024
-
Patent Title: Bicyclic inhibitors of histone deacetylase May. 21, 2024
-
Patent Title: Substituted pyridines as inhibitors of histone deacetylase Feb. 27, 2024
-
Patent Title: Hetero-halo inhibitors of histone deacetylase Jan. 02, 2024
-
Patent Title: Substituted piperidino compounds and related methods of treatment Sep. 19, 2023
-
Patent Title: Substituted macrocyclic compounds and related methods of treatment Jan. 03, 2023
-
Patent Title: Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties Dec. 27, 2022
-
Patent Title: Bicyclic inhibitors of histone deacetylase Mar. 29, 2022
-
Patent Title: Bicyclic inhibitors of histone deacetylase Jan. 18, 2022
-
Patent Title: Substituted pyridines as inhibitors of histone deacetylase Jan. 18, 2022
-
Patent Title: Hetero-halo inhibitors of histone deacetylase Feb. 16, 2021
-
Patent Title: Single chain fc fusion proteins Jan. 05, 2021
-
Patent Title: Compositions for modulating il-10 immunostimulatory and anti-inflammatory properties Jul. 02, 2019
-
Patent Title: Fusion polypeptides comprising mucin-domain polypeptide linkers Jan. 22, 2019
-
Patent Title: Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide Jul. 17, 2018
-
Patent Title: Peripherally acting opioid compounds Oct. 03, 2017
-
Patent Title: Ligands modified by circular permutation as agonists and antagonists Aug. 30, 2016
-
Patent Title: Peripherally acting opioid compounds Aug. 16, 2016
-
Patent Title: Ligands modified by circular permutation as agonists and antagonists Jun. 07, 2016
-
Patent Title: Fusion polypeptides comprising mucin-domain polypeptide linkers Mar. 29, 2016
-
Patent Title: Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide Oct. 13, 2015
-
Patent Title: Selective opioid compounds May. 26, 2015
-
Patent Title: Process for the synthesis of quaternary amine compounds May. 12, 2015
-
Patent Title: Polymorphic forms of naltrexone Mar. 10, 2015
-
Patent Title: Peripherally acting opioid compounds Feb. 24, 2015
-
Patent Title: Polymorphic forms of naltrexone May. 27, 2014
-
Patent Title: Polymorphic forms of naltrexone Mar. 05, 2013
-
Patent Title: Selective opioid compounds Jan. 15, 2013
-
Patent Title: Methods for administering aripiprazole Dec. 25, 2012
-
Patent Title: Methods for administering aripiprazole Dec. 25, 2012
-
Patent Title: Naltrexone long acting formulations and methods of use Apr. 05, 2011
-
Patent Title: Pulmonary delivery for levodopa Feb. 01, 2011
-
Patent Title: Residual solvent extraction method and microparticles produced thereby Jan. 25, 2011
-
Patent Title: Formulations for spray-drying large porous particles Oct. 05, 2010
-
Patent Title: Inhalable sustained therapeutic formulations Jul. 13, 2010
-
Patent Title: Particles for inhalation having sustained release properties Mar. 16, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded to ALKS from public contracts
Recent insights relating to ALKS
Recent picks made for ALKS stock on CNBC
ETFs with the largest estimated holdings in ALKS
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $ALKS stock a Buy, Sell, or Hold?
- What is the price target for $ALKS stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $ALKS stock?
- Who owns the most shares of $ALKS stock?
- What funds own $ALKS stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ALKS Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
- Address Dublin 4, L2
- Market Cap 7.0 billion
- Employees 2,050
- Industrial Classification Pharmaceutical Preparations
Alkermes Inc. plc (ALKS) Historical Stock Prices
Daily open, high, low, close, adjusted close and volume for Alkermes Inc. plc (ALKS).
Quiver Premium charts ALKS's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at ALKS, per a recent SEC DEF 14A filing. We estimate that the median employee at Alkermes plc. is paid $225,915.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|